|
Proportion of PWID HCV− (I)
|
25%
|
Average of values reported (10–40%)
|
Falade-Nwulia et al. [89]
|
|
Number of needles in circulation (N)
|
1,600,000
|
Increased by 33% due to additional syringe sources
|
Hunt and Parker [81]; German et al. [4]
|
|
Rate of needle sharing (s)
|
2.8%
|
Percent of injections with a shared needle
|
Park et al. [83]
|
|
Percentage of needles not bleached (d)
|
100%
| |
Bluthenthal et al. [84]
|
|
Proportion of PWID HCV+ (q)
|
75%
|
Average of values reported (60–90%)
|
Falade-Nwulia et al. [89]
|
|
Probability of HCV infections from a single injection (t)
|
3%
| |
Kwon et al. [86]; Kaplan and O’Keefe [85]
|
|
Number of sharing partners (m)
|
1.2
|
Per injection: ratio of receptive to distributive sharing
|
Park et al. [83]
|
|
SIF client reduction in needle-sharing (n)
|
70%
|
From Insite
|
Kerr et al. [40]
|
|
Number of SIF clients (N)
|
2100
|
Approximate monthly unique Insite injection room clients
|
Maynard [33]
|
|
Total PWID population (T)
|
20,950
|
Adjusted by authors from Baltimore MSA to City using race census data
|
Tempalski et al. [87]
|
|
Lifetime HCV treatment cost
|
$68,219
|
Adjusted for inflation
|
Razavi et al. [90]
|
